Clinical Trials Logo

Clinical Trial Summary

This is a randomized, open-label, crossover study to determine the effect of food when a combination tablet of SYR-322 and metformin hydrochloride ( hereinafter referred to as SYR-322-MET tablet) is orally administered under fasting conditions in the morning or after breakfast in Japanese healthy adult male subjects.


Clinical Trial Description

The primary objective of this clinical trial is to determine the effect of food on the pharmacokinetics of single oral dose administration of SYR-322-MET tablets in Japanese healthy adult male subjects ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02276274
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date June 2014
Completion date June 2014

See also
  Status Clinical Trial Phase
Completed NCT02629562 - Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects Phase 1
Completed NCT02286518 - TAK-114 Single- and Multiple-Dose Phase 1 Study Phase 1
Completed NCT01473108 - Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862 Phase 1
Completed NCT03424135 - A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions Phase 1
Completed NCT05437094 - Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 Phase 1
Completed NCT03074058 - Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet Phase 1
Completed NCT04511611 - Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects Phase 1
Completed NCT04511637 - Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects Phase 1
Completed NCT02113020 - A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects Phase 1
Completed NCT04364464 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1
Completed NCT06126861 - The Mass Balance Study of LP-168 in Healthy Subjects Phase 1
Completed NCT03517943 - A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects Phase 1
Completed NCT03136666 - Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design. Phase 1
Completed NCT03517930 - A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects Phase 1
Completed NCT04366622 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1